MEI Pharma Corp (MEIP) Total Debt to Capital

MEI Pharma, Inc. (MEIP) management is currently systematically closing research projects to return funds to shareholders. The business relies entirely on external contractors for synthesis and testing, as it owns no in-house facilities. This daily price chart on GURU.Markets for the individual debt-to-equity metric is 0.00. High margin potential remains due to the development of unique treatments for specific blood tumors.

meipharma.com (MEIP): Debt to Equity Ratio from 07/04/2022 to 09/11/2025

Metric breakdowns and analytics for MEI Pharma Corporation (MEIP)

- share price and consensus valuation forecast:

Stock Price MEI Pharma|MEIP - Consensus Target

- market capitalization details:

Market Capitalization MEI Pharma|MEIP - Enterprise Value

- book capitalization indicators:

Net Assets per Single Share MEI Pharma|MEIP - Accounting Capitalization|Market Capitalization to Book Value Ratio meipharma.com|MEIP - Cumulative Company Assets

- debt and liquidity details:

- net income and valuation ratios data:

MEIP - Company Net Income

Fundamental company valuation:MEI Pharma

This indicator is calculated as the quotient of total debt obligations to equity, determining the degree of financial leverage and the business's dependence on external financing. For MEI Pharma, Inc. (MEIP), which operates in the underserved segment of blood cancer therapy, the ratio of total liabilities to equity serves as a marker of the company's ability to sustain costly research and development without the risk of bankruptcy.

Competitor analysis for MEI Pharma, Inc.